1 Introduction Esophageal cancer (EC) is an aggressive malignancy and ranks as the sixth leading cause of cancer-related mortality worldwide (1). In 2020, an estimated 604,000 new cases and 544,000 deaths were reported globally (2), with China accounting for more than half of the total burden (3, 4). Despite progress in multimodal treatment, including surgery, chemotherapy, and radiotherapy (5), the overall prognosis remains poor, with a 5-year survival rate of approximately 30% (6).